TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine for Late-Life Treatment Resistant Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 50 years~* Major depressive disorder~* Non-responder to at least 2 FDA-approved antidepressants prescribed at a therapeutic dose, each for at least 6 weeks, or is a depression non-responder from an ongoing study of late-life depression at our research clinic.~Exclusion Criteria:~* Concomitant use of strong or moderate CYP3A4 inhibitor.~* Refusal to stop all opioids.~* Refusal to discontinue all alcohol.~* Refusal to discontinue benzodiazepines other than the equivalent of lorazepam 2 mg/day prescribed at a stable dose for at least the past 2 weeks.~* Hepatic impairment (AST/ALT \> 1.5 times upper normal.~* Lung disease requiring supplemental oxygen.~* Estimated creatinine clearance \<30 mL/min.~* Inability to provide informed consent.~* Depressive symptoms not severe enough (i.e., MADRS \< 10) at the baseline assessment.~* Dementia.~* Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms.~* Abuse of or dependence on alcohol or other substances within the past 3 months.~* Meets criteria for history of abuse or dependence upon opioids.~* High risk for suicide.~* Contraindication to buprenorphine.~* Inability to communicate in English.~* Non-correctable clinically significant sensory impairment.~* Unstable medical illness.~* Subjects taking psychotropic medications that cannot be safely tapered and discontinued prior to study initiation.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Buprenorphine (Type: EXPERIMENTAL): Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic (detectable HCV Ribonucleic acid (RNA) more than 6 months prior screening or histological diagnosis based on liver biopsy or fibroscan) HCV infection genotype 1 with HCV RNA level greater than 1,000 IU/mL~* Confirmed diagnosis of HIV-1 infection greater than 6 months before the screening visit~* CD4 count greater than 300 cells/mm3 at screening and no value less than 200 cells/mm3 within 6 months of screening visit~* HIV-1 RNA undetectable by an ultrasensitive assay at least once within 90 days of the screening visit~* No HIV RNA values greater than 200 copies/mL within 6 months of the screening visit~* Currently taking one of the permitted anti-HIV regimens for greater than or equal to12 weeks~Exclusion Criteria:~* Anticipated need to switch anti-HIV regimen from screening through the Telaprevir treatment period~* Infection or co-infection with HCV other than genotype 1~* Contraindication to the administration of Peg-IFN-alfa or RBV~* Hepatitis B virus (HBV) co-infection~* Acute or active condition of HIV-associated opportunistic infection within 6 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV) (Type: EXPERIMENTAL): All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinic to Community Connections - Broader Distribution

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Clinic staff: nurses (RN, LPN, BSN), community health workers, and others involved in maternal child health care~Exclusion Criteria:~Clinic staff: individuals not involved in maternal child health care or who do not consent to participate in study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Staff - Educational training (Type: EXPERIMENTAL): Nurses, community health workers, and others involved in maternal healthcare

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female children, adolescents and adults having completed the final visit of a previous study with levetiracetam (LEV)~* Subjects who were/are suffering from primary generalized (type II) epileptic seizures~* Subjects for whom the Investigator believes a reasonable benefit (efficacy or tolerability) from the long-term administration of LEV may be expected~Exclusion Criteria:~* Known clinically significant acute or chronic illness, for example: cardiac, renal or hepatic dysfunction, etc., which may impair reliable participation in the trial or necessitate the use of medication not allowed by protocol~* Concomitant use of any drug with possible central nervous system effects unless at a stable dose~* Concomitant use of any drug (other than hormonal treatment and the subject's normal anti-epileptic drugs (AEDs) that may influence the metabolism of the concomitant AED(s), except if the dose has been stable before entry in the study for sufficient length of time

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: EXPERIMENTAL): Subjects received treatment up to 1764 days during the Evaluation Period. Up to 4000 mg/day (or 80 mg/kg/day for children and adolescents less than 50 kg). Oral tablets of 166, 250, or 500 mg Levetiracetam twice daily (b.i.d.).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Atorvastatin Treatment in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~. Written informed consent must be obtained before any assessment is performed. 2. Male and female adults aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure.~3. Patients with moderate to very severe stable COPD (Stage II-IV) according to the GOLD guidelines.~4. Patients with a post-bronchodilator FEV1 \< 80% of the predicted normal, and a post-bronchodilator FEV1/FVC \< 0.70 at Visit 1.~5. Current or ex-smokers who have a smoking history of at least 10 pack years~Exclusion criteria~1. Pregnant or nursing (lactating) women~2. Women of child-bearing potential, unless they are using effective methods of contraception during dosing of study treatment. 5. 3. Patients with a clinically significant abnormality at Visit 1.~4. Patients with a clinically relevant laboratory abnormality at Visit 1 5. Patients with a history of malignancy of any organ system (including lung cancer).~6. Patients contraindicated for treatment with statins 7. Patients unable to perform acceptable spirometry and lung volumes procedures.~8. Patients who have had a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the 6 weeks prior to Visit 1.~9. Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1.~10. Patients requiring oxygen therapy (\>15 hr/day) on a daily basis for chronic hypoxemia 11. Patients with any history of asthma or onset of symptoms prior to age 40 years.~12. Patients with concomitant pulmonary disease, (e.g. lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, tuberculosis).~13. Patients with primary bronchiectasis. 14. Patients with a diagnosis of α-1 anti-trypsin deficiency. 15. Patients with pulmonary lobectomy or lung volume reduction surgery or lung transplantation.~16. Patients participating in or planning to participate in the active phase of a supervised pulmonary rehabilitation program during the study.~17. Patients receiving any medications in the class listed in Table 5.1 18. Use of other investigational drugs within 30 days prior to visit 1.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: ACTIVE_COMPARATOR): 40 mg of Atorvastatin once daily as add-on to Formoterol only 12 weeks therapy.
- Lactose tablet (Type: PLACEBO_COMPARATOR): One tablet taken once a day as add-on treatment to Formoterol baseline 12 weeks therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of simple or complex partial epilepsy that has been documented or witnessed~* an electroencephalogram (EEG) during the preceding 5 years that has a pattern consistent with the diagnosis of partial epilepsy~* during an 8-week baseline phase, patient must have at least 8 partial seizures while maintaining therapeutic levels of antiepileptic drugs (AEDs) and have no more than one seizure-free interval of up to 3 weeks~* and no seizure-free interval longer than 3 weeks~* good physical health.~Exclusion Criteria:~* Patients having solely generalized seizures or lacking documentation of partial epilepsy~* patients with generalized tonic-clonic seizures or other generalized epilepsies in the absence of an EEG consistent with partial epilepsy~* generalized seizures, which are defined by the EEG wave pattern~* seizures that lack an abnormal pulsation pattern on EEG~* females who are capable of having children

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Peer-Delivered Trauma-Specific Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be a member of INSIDE OUT, a peer-run wellness center~* Be at least 18 years old~* Have a history of trauma~* Meet DSM-IV diagnostic criteria for lifetime and current full or sub-threshold PTSD~* Meet DSM-IV diagnostic criteria for current substance abuse or dependence~* Be able to provide informed consent to participate in the study.~Exclusion Criteria:~* Live outside of catchment area~* Suicidal~* Pending immediate incarceration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peer led (Type: OTHER): Number sessions of the intervention of an evidenced based practice called Seeking Safety led by a Peer (6 sessions will be used to define treatment completion)
- Clinician led (Type: OTHER): Number intervention groups of an evidence based practice called Seeking Safety led by a master's level Clinician (6 sessions will be used to define treatment completion).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Emergency Department Healthcare Education Assessment and Response for Teen Relationships: A Pilot Feasibility Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* emergency department (ED) patient 14-19 years of age.~Exclusion Criteria:~* Developmental delay, severe illness, or cognitive impairment precluding informed consent/assent or completion of study activities, as determined by ED team or study team.~* Current ED evaluation for acute sexual assault/abuse.~* Current mental or behavioral health symptoms precluding completion of study activities, as determined by ED team or study team.~* Caregiver declines to step out to allow assent/consent in private or adolescent declines for caregiver to step out to allow assent/consent or participation in private.~* Adolescent is non-English speaking.~* Parent is non-English or non-Spanish speaking.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- ED-HEART (Intervention Arm) (Type: EXPERIMENTAL): All adolescents take a baseline survey in the Emergency Department (ED), receive Emergency Department Healthcare Education Assessment and Response for Teen Relationships (ED HEART) by a trained health educator, complete an exit survey while in the ED, complete a 6-week check-in to confirm contact information and aid retention, and complete a 12-week follow up survey.
- Enhanced Standard Care (Control Arm) (Type: NO_INTERVENTION): All adolescents take a baseline survey in the Emergency Department (ED), receive enhanced standard care (i.e., standard care + teen resource list), complete a 6-week check in to confirm contact information and aid retention, and complete a 12-week follow up survey.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medications Development for Drug Abuse Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion/Exclusion Criteria:~* Participants in this study will be males and females between the ages of 18 and 60 years.~* Applicants must be opioid dependent based upon the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (SCID); in addition, they must have an opioid positive urine during the screening process (or have evidence of opioid withdrawal).~* They must be healthy, with no significant medical illnesses (e.g., insulin dependent diabetes), and without significant psychiatric illness (e.g., schizophrenia) besides their drug dependence.~* Females will have a pregnancy test prior to study enrollment, and if found to be pregnant will be excluded and referred to a substance abuse program for pregnant women (the Center for Addiction and Pregnancy) on the campus.~* Volunteers will also be excluded if they have pre-admission hypotension (due to the use of clonidine in the study).~* Applicants with a history of seizures (including substance-related seizures, such as alcohol withdrawal related) will be excluded.~* Alcohol and/or sedative dependence will be specific exclusionary criteria (given the small risk of seizures associated with tramadol use).~* Allergies to any of the study medications will be grounds for exclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- buprenorphine (Type: ACTIVE_COMPARATOR): Sublingual buprenorphine/naloxone tablets (or placebo)
- clonidine (Type: ACTIVE_COMPARATOR): Oral clonidine tablets (or placebo)
- tramadol ER (Type: EXPERIMENTAL): Oral tramadol tablets (or placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must currently be diagnosed with either Type I or Type II diabetes mellitus.~* Must currently be performing self monitoring of blood glucose~* Must be between 18-70 years of age (inclusive).~* Must be able to read and follow study instructions in English.~Exclusion Criteria:~* Pregnant (self reported)~* History of poor blood circulation.~* Any skin condition on his or her fingers that prevents blood sampling.~* History of a bleeding disorder.~* Neuropathy or other condition affecting sensation in the hands.~* Self-reported blood borne infection (e.g., HIV, hepatitis B or C \[non A, non B\], syphilis, malaria, babesiosis, brucellosis, leptospirosis, arboviral infections, relapsing fever, T lymphotropic virus Type 1, Creutzfeldt-Jakob disease).~* Currently participating in another study~* Employed by BD, J\&J, Roche or the Clinical Site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: OTHER): In Visit 1 subjects tested BD/33G, OTM/33G, and OTM/28G devices. In Visit 2 subjects tested BD/33G and OTM/28G. See purpose for additional information.
- Arm B (Type: OTHER): In Visit 1 subjects tested BD/33G, OTM/33G and OTU/28G devices. In Visit 2 subjects tested BD/33G and OTU/28G. See purpose for additional information.
- Arm C (Type: OTHER): In Visit 1 subjects tested BD/33G, OTM/33G and ACC/28G devices. In Visit 2 subjects tested BD/33G and ACC/28G. See purpose for additional information.
- Arm D (Type: OTHER): In Visit 1 subjects tested BD/33G, OTM/33G and OTM/28G devices. In Visit 2 subjects tested OTM/33G and OTM/28G. See purpose for additional information.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Female subjects ages 18 to 45~2. Subjects with American Society of Anesthesiologists (ASA) Class I or II~3. Subjects with elective primary or repeat cesarean delivery~4. Subjects who receive combined spinal epidural anesthesia~5. English and non-English speaking subjects will be included in the study~Exclusion Criteria:~1. Female subjects \<18 years of age~2. Subjects requiring emergent cesarean delivery~3. History of placenta accrete~4. Multiple gestation pregnancy~5. ASA status III or higher~6. Current history of pregnancy induced hypertension, pre-eclampsia, or eclampsia~7. History of any chronic medication use (other than prenatal vitamins), including inhaler medications~8. Current urinary tract infection, pneumonia, or otitis media

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia
- Metoclopramide, Ondansetron (Type: ACTIVE_COMPARATOR): 10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
- Acupressure Point P6 stimulator (Type: EXPERIMENTAL): Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete